全文获取类型
收费全文 | 120036篇 |
免费 | 6443篇 |
国内免费 | 149篇 |
专业分类
耳鼻咽喉 | 1869篇 |
儿科学 | 5415篇 |
妇产科学 | 4056篇 |
基础医学 | 16518篇 |
口腔科学 | 2967篇 |
临床医学 | 8616篇 |
内科学 | 22965篇 |
皮肤病学 | 3417篇 |
神经病学 | 9307篇 |
特种医学 | 5445篇 |
外国民族医学 | 32篇 |
外科学 | 19683篇 |
综合类 | 1621篇 |
一般理论 | 34篇 |
预防医学 | 6077篇 |
眼科学 | 3509篇 |
药学 | 8218篇 |
中国医学 | 339篇 |
肿瘤学 | 6540篇 |
出版年
2018年 | 1036篇 |
2017年 | 877篇 |
2016年 | 1194篇 |
2015年 | 1316篇 |
2014年 | 1749篇 |
2013年 | 2530篇 |
2012年 | 3378篇 |
2011年 | 3446篇 |
2010年 | 2138篇 |
2009年 | 2063篇 |
2008年 | 3507篇 |
2007年 | 3726篇 |
2006年 | 3863篇 |
2005年 | 3950篇 |
2004年 | 3901篇 |
2003年 | 3726篇 |
2002年 | 3693篇 |
2001年 | 7168篇 |
2000年 | 7138篇 |
1999年 | 5956篇 |
1998年 | 1612篇 |
1997年 | 1541篇 |
1996年 | 1341篇 |
1995年 | 1247篇 |
1994年 | 1127篇 |
1993年 | 1143篇 |
1992年 | 3842篇 |
1991年 | 3659篇 |
1990年 | 3637篇 |
1989年 | 3409篇 |
1988年 | 3043篇 |
1987年 | 2935篇 |
1986年 | 2848篇 |
1985年 | 2653篇 |
1984年 | 1963篇 |
1983年 | 1607篇 |
1982年 | 935篇 |
1981年 | 914篇 |
1980年 | 770篇 |
1979年 | 1835篇 |
1978年 | 1347篇 |
1977年 | 1116篇 |
1976年 | 941篇 |
1975年 | 1188篇 |
1974年 | 1227篇 |
1973年 | 1217篇 |
1972年 | 1056篇 |
1971年 | 996篇 |
1970年 | 898篇 |
1969年 | 800篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
C. Arce-Salinas J. L. Aguilar-Ponce C. Villarreal-Garza F. U. Lara-Medina D. Olvera-Caraza A. Alvarado Miranda D. Flores-Díaz A. Mohar 《Breast cancer research and treatment》2014,146(1):183-188
Obesity and overweight are established risk factors for the development of breast cancer. They are also associated with poor prognosis for higher risk of disease recurrence and lower overall survival (OS). The aim of this study was to evaluate the influence of overweight and obesity in OS in patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy. This is a retrospective analysis that included 819 patients diagnosed with LABC between January 2004 and December 2008. The patients were treated with neoadjuvant chemotherapy (NAT) based on anthracyclines, taxanes, or both, followed by surgery. For comparison, patients were divided into the normal weight (NW) group or the overweight/obesity (OW/OB) group. The prevalence of overweight/obesity was 74 %. General characteristics of the patients, including age, tumor size, clinical stage, nuclear grade, hormone receptors, and HER2 expression, were similar between both groups. At a median follow-up of 28 months, we found a statistically significant difference in OS between the two groups, achieving a 91.5 % in NW patients versus 85.9 % in the OW/OB group (P = 0.050). Cox multivariate analysis demonstrated that obesity was an independent factor for poor prognosis, with a hazard ratio of 1.79 (95 % CI (Confidence Interval) 1.09–2.96; P = 0.022). This is the first Mexican study that confirms the role of OW/OB as a risk factor for poor outcome among patients with LABC. Obesity in our country is a public health problem and requires strong preventive intervention strategies for its control, especially among patients diagnosed with breast cancer. 相似文献
992.
Diabetic peripheral neuropathy in people with type 2 diabetes is poorly managed because of its insidious onset, delayed diagnosis and more complex aetiology resulting from the contribution of not only hyperglycaemia, but also ageing, hyperlipidaemia, hypertension and obesity. Because there is no US Food and Drug Adminstration-approved disease-modifying therapy for diabetic peripheral neuropathy, the key to ameliorating it in type 2 diabetes has to be through earlier diagnosis and timely multi-factorial risk factor reduction. The management of painful diabetic peripheral neuropathy also requires a detailed appraisal of the choice of therapy, taking into account efficacy, patient wishes, comorbidities, side effect profile and potential for abuse. 相似文献
993.
N. Müller T. Lehmann A. Klöss C. Günster C. Kloos U. A. Müller 《Diabetic medicine》2020,37(8):1326-1332
994.
995.
996.
997.
Mehta Gautam U. Muelleman Thomas J. Brackmann Derald E. Gidley Paul W. 《Journal of neuro-oncology》2020,149(3):437-445
Journal of Neuro-Oncology - This study was performed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of the immunomodulatory agent, lenalidomide, when administered... 相似文献
998.
R. Ferrara S. Pilotto U. Peretti M. Caccese S. Kinspergher L. Carbognin 《Expert opinion on pharmacotherapy》2016,17(8):1113-1129
Introduction: Although the advent of target therapy for lung cancer has brought about outstanding results, this benefit is confined to a subgroup of molecularly selected patients, whereas for most non-small cell lung cancer (NSCLC) patients, chemotherapy still represents the milestone of treatment. Since their introduction into clinics, microtubule targeting agents (MTA), including vinca alkaloids and taxanes, have been extensively used for NSCLC in different settings and combinations.Areas Covered: In this review, MTA are classified according to their mechanism of action, with a focus on the most common mechanisms of resistance. Moreover, an overview of the most remarkable clinical data regarding MTA in adjuvant, neoadjuvant and advanced setting is provided. Finally, the novel mitotic kinases inhibitors are described according to their different mechanism of action and clinical activity compared to MTA.Expert Opinion: Unfortunately, the awaited benefit deriving from the actually available chemotherapeutic regimens for advanced NSCLC has reached a plateau. In this scenario, the identification of reliable predictive biomarkers represents a major challenge. Moreover, different schedules for MTA administration are currently under investigation, such as the combination of MTA with other drugs able to bypass the resistance derived from the ‘mitotic slippage’ and the use of metronomic administration of spindle poisons with anti-angiogenic or immunomodulatory agents. 相似文献
999.
1000.